Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder

Official title: Remote Treatment With Incentives for Sobriety (TRIS): A Randomized Controlled Trial of a Contingency Management App for Alcohol Use Disorder

Run by University of Sao Paulo General Hospital · NCT07735585 · Data updated 2026-11-12

A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment130 (estimated)
SponsorUniversity of Sao Paulo General Hospital
Academic / other
Locations1 site (São Paulo, São Paulo)
StatusRecruiting
StartedFebruary 19, 2026
Main results expectedAugust 2027
Study endsDecember 2027
Registry record updatedJuly 30, 2026
Trial IDNCT07735585 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–70 with a current AUD diagnosis, seeking treatment at AME Vila Maria or Instituto Perdizes in São Paulo, able to use a smartphone and read Portuguese, with BrAC 0.00 at consent.

Probably not a fit

Individuals who do not respond to contingency incentives or who have safety concerns or unreliable access to a smartphone may see little benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial tests whether adding TRIS, a Brazilian mobile app integrated with a Bluetooth breathalyzer, to standard outpatient care increases days of verified abstinence from alcohol. Participants are randomized to receive 12 weeks of remote contingency management via TRIS plus usual care or usual care with remote monitoring but no incentives. Daily BrAC samples are submitted through the app, and incentives are provided only when all three daily samples are alcohol-negative and on time. The study enrolls 130 adults with AUD from two public clinics in São Paulo and uses a 1:1 randomization. Primary outcome is the number of biochemically verified abstinent days during the 12-week period; secondary outcomes include patterns of use, adherence, usability, withdrawal, craving, and related symptoms.

Why it matters

Potential benefit: If successful, TRIS-based contingency management could help more patients maintain abstinence and improve engagement in treatment.

How similar studies have gone: Contingency management approaches for AUD have shown benefit in prior research, supporting exploration of a remote, app-based delivery.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Able to read and speak Portuguese.
* Provide signed informed consent.
* Age 18 to 70 years.
* Alcohol consumption within the past month.
* Current diagnosis of Alcohol Use Disorder (AUD).
* Seeking treatment for AUD at AME Vila Maria or Instituto Perdizes.
* Breath alcohol concentration (BrAC) of 0.00 at the time of consent.
* Own and be able to operate a smartphone with an active mobile service plan.
* Smartphone compatible with the Bluetooth frequency required for the BACtrack breathalyzer.

Exclusion Criteria:

* Crack cocaine use within the past 90 days.
* Any seizure episode within the past 12 months.
* Diagnosis of a psychotic disorder (DSM-5).
* Suicide attempt within the past two years.
* Any medical or psychiatric condition that may compromise safe participation, as determined by the study medical director.

Where it's running

  • IPER Research Center
    São Paulo, São Paulo, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.